io-108
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2021 (NCT05054348)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- LILRB2ANTAGONIST
LILRB2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05508100 | Phase 1 | Sep 9, 2022 | Immune-Onc Therapeutics Inc |
| NCT05054348 | Phase 1 | Sep 30, 2021 | Immune-Onc Therapeutics Inc |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immune-Onc Therapeutics Inc | For profit | 2 | 2 | 1 | 2021 |
1 organizations
Page 1 / 1